Personalis and ClearNote Health Announce Partnership to Advance Epigenomic TechnologyBusiness Wire • 01/30/24
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling AssayBusiness Wire • 01/16/24
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash BalanceBusiness Wire • 01/05/24
Personalis Extends Cash Position Into 2026, Provides Update on Key InitiativesBusiness Wire • 12/04/23
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer TestingBusiness Wire • 11/28/23
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in CancerBusiness Wire • 10/26/23
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD TechnologyBusiness Wire • 10/21/23
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023Business Wire • 10/19/23
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical ComplianceBusiness Wire • 10/18/23
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare ConferenceBusiness Wire • 08/29/23
Personalis Files Second Patent Infringement Suit Against Foresight DiagnosticsBusiness Wire • 06/26/23
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal CancerBusiness Wire • 05/16/23
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast CancerBusiness Wire • 05/02/23